I am quite appreciative toward my research publications and the website. You’ve been more than my readers for you’re also my teachers, as well as, my friends. I strongly believe that I learn from you, just as much as, you would learn from me. Many of you are far more accomplished than me in your respective fields.
You have more intelligence needed to analyze stocks. Yet the key is to stay with your “circle of competence.” Instead of listening to WS pundits or me, you’d outperformed the market in the long term if you listen to yourself while being patient and willing to perform independent research.
While I could not speak for all, I found that biopharmaceutical analysis is tough. Despite my background as an MD and a researcher, I found it’s difficult to analyze/appraise these firms and their drugs. Years ago, my group of experts including chemist, PhD, and MDs used to analyze biopharma stocks; yet the exercises were equally challenging.